Hemostats Market Analysis & Forecast: 2026-2033
The Hemostats market is anticipated to grow at a CAGR of 8.5% with USD 3.82 Bn in 2026 and is expected to reach USD 6.22 Bn in 2033. Rising volumes of surgical procedures performed across the world coupled with an increasing number of trauma and accident injury cases (India, annually, 0.15 million, and as per WHO, roughly 1 in 3 of these deaths result from road traffic crashes) are expected to foster growth of the global hemostats market. Moreover, the use of these instruments can be found not only in trauma injury surgical procedures but also in complex surgeries that involve significant blood loss due to larger incisions made on the patients’ skin such as open-heart surgery, hernia repair surgery, joint repair surgery, cardiovascular surgery, and other neurologic surgeries.
Rochester-Carmalt Hemostatic Forceps is projected to account for the largest share of instrument type in 2026, representing approximately 45% of the total volume. Their exceptional versatility along with robust design is one of the growths inducing factor, characterized by multiple surgical specialties. The Rochester-Carmalt forceps are differed by their broader jaw design as well as deeper serrations, which provide better gripping capability for larger tissue masses as well as thicker vascular structures.
This design advantage has made them particularly valuable in gynecological devices, general surgery, as well as emergency medicine applications. Gynecological surgeries are a big part of women's healthcare. Over 600,000 hysterectomies are done each year in the US.
According to the American College of Surgeons, these forceps have become the preferred choice in major surgical centers owing to their ability to provide reliable hemostasis in fluctuating surgical environments where conventional hemostatic instruments may prove inadequate.
To learn more about this report, Request Free Sample
Based on end user, hospitals dominate the market, accounting for a significant 50% share in 2026, the segment is propelling due to their comprehensive surgical capabilities, high patient volume, and extensive procurement budgets for advanced medical devices. Hospital admissions totaled nearly 1.2 million in 2024/25. Hospitalized patients in Q2 2025 were on average nearly 30% more likely to survive than expected given the severity of their illnesses compared to Q4 2019.
Hospitals are the main part of healthcare worldwide and handle the most difficult surgeries that need advanced hemostatic solutions. According to the World Health Organization, hospitals worldwide perform millions of surgical procedures annually, with cardiovascular, orthopedic, as well as general surgeries being the most common, all of which heavily depend on hemostatic an to control bleeding as well as makes sure patient safety.
Data from the American Hospital Association shows that big hospitals usually keep many types of hemostatic products, like mechanical, active, and flowable hemostats, for different surgeries. Large hospitals that handle complex cases often use more of these high-quality products.
Mechanical Hemostats are tools used to stop bleeding during surgery by pressing on blood vessels or using special materials that help blood clot. Common types include gelatin sponges and foams, collagen mats and fleeces, microfibrillar collagen, and thrombin-soaked gelatin matrices. These products make a physical barrier or encourage clotting to control bleeding quickly as well as safely.
Prominent companies like Johnson & Johnson, Baxter, Pfizer, etc., make mechanical hemostats. For example, Surgicel by Johnson & Johnson works in 85% of cases within 10 minutes, FloSeal by Baxter reduces bleeding time by 50% in heart surgeries, and Gelfoam by Pfizer is used in over 10,000 hospitals worldwide. Overall, mechanical hemostats help reduce surgery time by 15–20% and lower post-surgery bleeding problems by 30%, making operations safer and more efficient.
Active Hemostats are products that help the body stop bleeding faster using natural clotting agents like thrombin and fibrinogen. Common types include recombinant thrombin products, fibrin sealants, platelet-rich plasma (PRP) concentrates, as well as autologous fibrin adhesives. These products fasten up the natural clotting process during surgery.
Major companies like CSL Behring, Grifols, Takeda, etc., make active hemostats. For example, Artiss by CSL Behring lowering blood transfusions by 40% in complex heart surgeries, Vistaseal by Grifols shows 95% success in liver surgery, as well as TachoSil by Takeda cuts re-operation rates by 25%. Overall, active hemostats improve patient outcomes, reduce blood transfusion needs by 35%, and shorten hospital stays by 20%.
|
Current Event |
Description and its Impact |
|
FDA Expands Approval for Hemostatic Devices |
|
|
EU Medical Device Regulation (MDR) Enforcement |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America account 40% market share in 2026, its advanced medical technology adoption, as well as a strong regulatory framework is the growth inducing factor, ensuring high-quality hemostats products reach healthcare facilities efficiently.
The region benefits from a well-established network of leading medical device manufacturers such as Johnson & Johnson, Medtronic, and Baxter International, all headquartered within North America, providing seamless supply chain management and rapid product innovation cycles. There was 955 Medical Device Manufacturing in the U.S. businesses as of 2025, an increase of 1.8% from 2024.
The presence of world-renowned medical institutions like Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, etc., drives demand for sophisticated hemostatic agents as well as devices, as these facilities consistently perform complex surgical procedures that require advanced bleeding control solutions.
The Asia-Pacific region is poised to be the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 7.5%. The expanding healthcare infrastructure, increasing surgical procedures, as well as growing awareness about advanced hemostatic solutions in the region are the factors fueling the market growth.
The remarkable growth trajectory is primarily attributed to countries like China, India, and Southeast Asian nations where government healthcare initiatives are significantly boosting demand for quality medical devices. China is the world’s second largest healthcare industry with an estimated value exceeding $1 trillion in 2024, and over $1.5 trillion by 2029, with 60 percent of health expenditures currently coming from the government.
The region's growth is further accelerated by the emergence of local manufacturing capabilities, with companies like Starch Medical in China and Meril Life Sciences in India developing innovative hemostatic solutions tailored to regional needs.
The U.S. contributes the highest share in the hemostats market in North America due to its advanced medical device manufacturing capabilities, along with substantial investment in surgical innovation. Moreover, the presence of leading medical device manufacturers, extensive surgical procedure volumes, as well as strong regulatory frameworks that encourage innovation are bolstering the market.
The U.S. Food and Drug Administration's streamlined approval processes for hemostatic agents have facilitated rapid market entry for new products, ensuring a competitive landscape that fuels continuous advancement.
For example, the American College of Surgeons National Surgical Quality Improvement Program reported that over 15 million surgical procedures are conducted annually in participating hospitals across the United States, making high demand for advanced hemostatic solutions.
China contributes highest share in market due to its robust healthcare infrastructure development, extensive manufacturing capabilities, as well as major government investments in medical technology advancement. The country is further stimulated by the massive population base requiring surgical interventions, rapidly aging demographics, as well as the government's Healthcare Reform 2020 initiative that allocated substantial resources toward modernizing medical facilities across tier-one and tier-two cities.
China's dominance is exemplified by the recent establishment of multiple state-of-the-art cardiac surgery centers in Beijing and Shanghai, which have dramatically increased the demand for advanced hemostatic agents and devices.
Some of the major key players in Hemostats Market include, B.Braun Melsungen AG, CareFusion Corporation, Pentax Medical, Shanghai Medical Instruments, Teleflex Medical, Asa Dental, J & J Instruments, and others
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.82 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.5% | 2033 Value Projection: | USD 6.22 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
B.Braun Melsungen AG, CareFusion Corporation, Pentax Medical, Shanghai Medical Instruments, Teleflex Medical, Asa Dental, J & J Instruments |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
